Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP CLO & General Counsel, received a grant of 19,350 non-qualified stock options on 01/02/2026. Each option gives the right to buy one share of Ionis common stock at an exercise price of $79.67 under the company’s Amended and Restated 2011 Equity Incentive Plan.
None of the options were exercisable on the grant date. Instead, 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. The remaining options will then vest and become exercisable in 36 equal monthly installments over the following three years, creating a four-year total vesting period tied to continued service.
Ionis Pharmaceuticals reported an equity award for its Chief Executive Officer, Brett P. Monia. On 01/02/2026, he received a grant of 85,410 non-qualified stock options under the company’s Amended and Restated 2011 Equity Incentive Plan, with an exercise price of $79.67 per share.
According to the vesting terms, the option was not exercisable on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, and the remaining shares will vest in 36 equal monthly installments over the following three years, ending before the option’s 01/01/2036 expiration date.
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, received a new stock option award. On 01/02/2026 she was granted a non-qualified stock option to buy 9,100 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.
The option was not exercisable for any shares on the grant date. According to the vesting schedule, 25% of the shares will vest and become exercisable on 01/02/2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments over the following three years.
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, filed an initial ownership report showing her equity stake in the company. She directly holds 7,740 shares of Ionis common stock.
She also holds multiple non-qualified stock options to buy Ionis common stock, including grants covering 12,000, 10,000, 11,500, 19,800, 19,895 and 28,951 shares with exercise prices ranging from $32.60 to $60.89 and expiration dates between 2027 and 2035.
In addition, Kordasiewicz has 31,949 restricted stock units (RSUs). These RSUs were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan on January 15 of 2022, 2023, 2024 and 2025, and vest in four equal annual installments, settling in Ionis common shares or cash as determined by the company.
Ionis Pharmaceuticals reported that its EVP, Finance & CFO, Elizabeth L. Hougen, received a grant of stock options on 01/02/2026 under the company’s Amended and Restated 2011 Equity Incentive Plan. The award covers 25,770 non-qualified stock options with an exercise price of $79.67 per share and was granted at no cost to the executive.
None of the options were exercisable on the grant date. 25% of the options will vest and become exercisable on 01/02/2027, with the remaining options vesting in 36 equal monthly installments over the following three years, and the options are scheduled to expire on 01/01/2036.
Ionis Pharmaceuticals reported a routine equity grant to executive Shannon L. Devers, its EVP and Chief Human Resources Officer. On 01/02/2026, Devers received a non-qualified stock option to buy 19,350 shares of Ionis common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.
The option was not exercisable for any shares on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, ending before the option’s expiration on 01/01/2036.
Ionis Pharmaceuticals executive Brian Birchler received a new stock option grant. On 01/02/2026, he was awarded a non-qualified stock option to buy 19,350 shares of Ionis common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan. The filing shows this as a direct holding of derivative securities.
The option was not exercisable in any amount on the grant date. According to the vesting schedule, 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. The remaining shares will then vest and become exercisable in 36 equal monthly installments over the following three years.
Ionis Pharmaceuticals executive C. Frank Bennett, EVP and Chief Scientific Officer, received a new stock option grant. On 01/02/2026, he was granted a non-qualified stock option to purchase 19,350 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan. The option expires on 01/01/2036. Following this grant, he beneficially owned 19,350 derivative securities related to these options.
The option was not exercisable as of 01/02/2026. Vesting is time-based: 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, with the remaining shares vesting and becoming exercisable in 36 equal monthly installments over the subsequent three years, providing long-term equity-based compensation tied to continued service.
Ionis Pharmaceuticals director reports stock option exercise
A director of Ionis Pharmaceuticals, Inc. (IONS) reported exercising a non-qualified stock option on 11/18/2025. The option, with an exercise price of $24.42 per share and originally scheduled to expire on 06/30/2026, was exercised for 16,000 shares of common stock. Following this transaction, the reporting person holds 16,000 shares of Ionis common stock directly and 64,035 shares indirectly through a trust. The filing notes that the acquired shares resulted from the option exercise before its scheduled expiration.
Ionis Pharmaceuticals director reports option exercises and share sales. On 11/19/2025, the reporting person exercised non-qualified stock options to acquire 12,000 Ionis common shares at $40.05 and 32,000 shares at $63.90. The same day, they sold 12,000 shares and another 32,000 shares at a weighted average price of $72.1325 per share, in multiple trades within a stated price range. After these transactions, the insider beneficially owned 46,086 Ionis shares directly, and both option grants referenced in the filing were fully exercised, leaving no remaining derivative securities from those specific awards.